Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen Resistant Prostatic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06764485
What this trial is testing

Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Celgene 960
Early research (Phase 1)Study completedNCT02162836
What this trial is testing

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Janssen Pharmaceutical K.K. 6
Early research (Phase 1)Not Yet RecruitingNCT07756593
What this trial is testing

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Prostate Cancer
Washington University School of Medicine 30
Testing effectiveness (Phase 2)UnknownNCT04926155
What this trial is testing

The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Sun Yat-sen University 234
Testing effectiveness (Phase 2)Study completedNCT00919035
What this trial is testing

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Oncology Specialists, S.C. 21
Early research (Phase 1)Ended earlyNCT05241613
What this trial is testing

AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc 28
Not applicableStudy completedNCT04057859
What this trial is testing

PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training

Who this might be right for
Cancer of the Prostate
CMX Research 271
Testing effectiveness (Phase 2)UnknownNCT01487902
What this trial is testing

The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Asan Medical Center 90
Testing effectiveness (Phase 2)Ended earlyNCT03577028
What this trial is testing

Study of HPN424 in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 104
Testing effectiveness (Phase 2)Looking for participantsNCT06100705
What this trial is testing

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Yale University 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT05057013
What this trial is testing

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Who this might be right for
Bladder CancerTriple Negative Breast CancerCastration-resistant Prostate Cancer+11 more
Cancer Research UK 81
Not applicableLooking for participantsNCT07677267
What this trial is testing

Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Novartis Pharmaceuticals 1,067
Early research (Phase 1)Study completedNCT05293496
What this trial is testing

MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorCastration-Resistant Prostatic CancerMalignant Melanoma+4 more
MacroGenics 31
Testing effectiveness (Phase 2)Looking for participantsNCT04946370
What this trial is testing

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 52
Large-scale testing (Phase 3)Ended earlyNCT04876651
What this trial is testing

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Ltd 16
Testing effectiveness (Phase 2)Study completedNCT02130700
What this trial is testing

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298
What this trial is testing

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Who this might be right for
Prostatic Neoplasm
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Study completedNCT01615120
What this trial is testing

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Who this might be right for
Prostate Cancer
GTx 77
Early research (Phase 1)Looking for participantsNCT07570979
What this trial is testing

Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 208
Early research (Phase 1)Study completedNCT01351688
What this trial is testing

An Open Label Prostate Cancer Study in Japanese Patients

Who this might be right for
Prostate Cancer
AstraZeneca 13
Next Page